HealthcareServices

Cardiovascular Genetic Testing Market Insights Report: Opportunities and Drivers 2030

March 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the cardiovascular genetic testing market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Cardiovascular Genetic Testing Market between 2026 and 2030?

The cardiovascular genetic testing market size has seen swift expansion in recent years. It is projected to increase from $3.93 billion in 2025 to $4.35 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.8%. The growth observed in prior periods can be attributed to heightened awareness regarding inherited cardiovascular disorders, advancements in molecular diagnostic capacities, a decrease in genetic sequencing costs, the expanding availability of genetic counseling services, and increased investigation into cardiovascular genomics.

The cardiovascular genetic testing market is projected to experience swift expansion in the coming years. By 2030, its valuation is anticipated to reach $6.62 billion, exhibiting a compound annual growth rate (CAGR) of 11.0%. This projected increase over the forecast timeframe can be linked to a heightened demand for precise medical strategies, the expanding uptake of widespread genetic screening, the broadening application of AI-powered variant analysis, the deeper incorporation of genomics into medical decision processes, and a reinforced emphasis on proactive cardiovascular health management. Key developments anticipated during this period involve a greater embrace of genetic risk prediction, the growing utilization of multi-gene panel assessments, the deeper merger of bioinformatics and AI-driven analytics, the wider availability of pharmacogenomic testing, and an intensified commitment to individualized cardiovascular patient care.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33054&type=smp

Which Drivers Are Expected To Impact The Cardiovascular Genetic Testing Market During The Forecast Period?

The increasing prevalence of cardiovascular diseases is projected to drive the growth of the cardiovascular genetic testing market. These conditions, referred to as CVDs, are a collection of ailments affecting the heart and blood vessels, including heart attacks, strokes, and hypertension. The rise in cardiovascular diseases is largely attributed to increasingly sedentary lifestyles associated with urbanization, which contribute to issues such as obesity, hypertension, and various metabolic disorders. The higher incidence of cardiovascular diseases fuels the demand for cardiovascular genetic testing, as early detection of genetic risks enables the implementation of personalized prevention and treatment plans, thus lowering the probability of severe heart complications. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, stated that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, an increase of 4.0% from 224.4 per 100,000 in 2023. Consequently, the growing occurrence of cardiovascular disease is a primary catalyst for the expansion of the cardiovascular genetic testing market.

Which Segments Are Driving Activity In The Cardiovascular Genetic Testing Market?

The cardiovascular genetic testing market covered in this report is segmented –

1) By Testing Type: Predictive Testing; Carrier Testing; Prenatal And Newborn Testing; Diagnostic Testing; Pharmacogenomic Testing; Other Testing Types

2) By Disease: Inherited Cardiomyopathies; Hypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Arrhythmia; Aortopathies; Other Diseases

3) By Technology: Cytogenetic Testing; Biochemical Testing; Molecular Testing

4) By Application: Chromosome Analysis; Genetic Disease Diagnosis; Cardiovascular Disease Diagnosis; Other Applications

5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutions; Genetic Counseling Centers; Pharmaceutical Companies; Direct-To-Consumer Testing

Subsegments:

1) By Predictive Testing: Presymptomatic Risk Assessment; Familial Variant Screening; Polygenic Risk Evaluation; Late Onset Disease Prediction; Susceptibility Gene Testing

2) By Carrier Testing: Autosomal Recessive Carrier Screening; Linked Carrier Screening; Expanded Carrier Screening Panels; Single Gene Carrier Screening; Family History Based Carrier Testing

3) By Prenatal And Newborn Testing: Non Invasive Prenatal Genetic Testing; Invasive Prenatal Diagnostic Testing; Newborn Metabolic Screening; Congenital Heart Disease Genetic Screening; Neonatal Gene Panel Testing

4) By Diagnostic Testing: Single Gene Diagnostic Testing; Multigene Panel Diagnostic Testing; Whole Exome Diagnostic Testing; Whole Genome Diagnostic Testing; Variant Confirmation Testing

5) By Pharmacogenomic Testing: Drug Response Gene Testing; Adverse Drug Reaction Risk Testing; Dose Optimization Genetic Testing; Anticoagulant Response Testing; Cardiovascular Drug Metabolism Testing

6) By Other Testing Types: Cascade Family Testing; Population Based Genetic Screening; Research Use Genetic Testing; Confirmatory Follow Up Testing; Clinical Trial Genetic Testing

How Are New Market Trends Shaping The Landscape Of The Cardiovascular Genetic Testing Market?

Major companies operating in the cardiovascular genetic testing market are concentrating on developing innovative solutions, such as clinician-ordered tests, to help ensure the medical necessity of tests and tailor them to the patient’s specific health condition, thereby reducing unnecessary testing and associated costs. A clinician-ordered test is defined as a medical examination or diagnostic procedure requested by a healthcare professional to evaluate, monitor, or guide the management of a patient’s health condition. For instance, in September 2025, Mass General Brigham, a US-based not-for-profit integrated academic healthcare system, in collaboration with Broad Clinical Labs, a US-based genomic data generation laboratory, and Mass General Brigham Laboratory for Molecular Medicine, a US-based molecular diagnostic laboratory, introduced a genetic test that assesses inherited risk for eight cardiovascular conditions. This clinician-ordered test is available on a self-pay basis and evaluates genetic predisposition to eight conditions, which include atrial fibrillation, coronary artery disease, type 2 diabetes, elevated lipoprotein(a), hypercholesterolemia, hypertension, thoracic aortic aneurysm, and venous thromboembolism. Its development incorporated genotype and clinical data from 236,393 participants in the NIH’s All of Us Research Program. Publicly available polygenic risk scores for each condition were integrated using PRSmix, an elastic-net modeling approach that combines multiple component scores into a single, comprehensive risk score per disease. High-resolution genetic data is obtained through a clinical blended genome-exome assay at Broad Clinical Labs, while the CLIA-certified Mass General Brigham Laboratory for Molecular Medicine is responsible for interpreting the results and generating patient-friendly reports.

Which Major Firms Are Strengthening Their Position In The Cardiovascular Genetic Testing Market?

Major companies operating in the cardiovascular genetic testing market are Labcorp Holdings Inc., Quest Diagnostics Inc., ICON plc, Illumina Inc., Apollo Hospitals, OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., and Health in Code SL.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cardiovascular-genetic-testing-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Cardiovascular Genetic Testing Market?

North America was the largest region in the cardiovascular genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cardiovascular Genetic Testing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33054&type=smp

Browse Through More Reports Similar to the Global Cardiovascular Genetic Testing Market 2026, By The Business Research Company

Cardiovascular Clinical Trials Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiovascular-clinical-trials-global-market-report

Genetic Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

Direct To Consumer Dtc Genetic Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/direct-to-consumer-dtc-genetic-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795